aTyr Pharma Inc. Daily Stock Analysis

Daily Stock Analysis, LIFE, aTyr Pharma Inc, priceseries

aTyr Pharma Inc. Daily Stock Analysis
Stock Information
Open
5.02
Close
4.85
High
5.09
Low
4.76
Previous Close
5.01
Daily Price Gain
-0.16
YTD High
8.25
YTD High Date
Jan 5, 2022
YTD Low
4.76
YTD Low Date
Mar 7, 2022
YTD Price Change
-2.69
YTD Gain
-35.68%
52 Week High
13.10
52 Week High Date
Sep 23, 2021
52 Week Low
3.50
52 Week Low Date
May 11, 2021
52 Week Price Change
0.50
52 Week Gain
11.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2017
45.50
Feb 23. 2017
48.79
14 Trading Days
7.23%
Link
LONG
Sep 12. 2017
42.70
Oct 16. 2017
79.01
24 Trading Days
85.03%
Link
LONG
Jun 14. 2018
13.47
Jun 26. 2018
14.58
8 Trading Days
8.26%
Link
LONG
Jul 12. 2018
13.58
Jul 13. 2018
14.42
1 Trading Days
6.19%
Link
LONG
Sep 17. 2018
10.50
Oct 1. 2018
11.14
10 Trading Days
6.12%
Link
LONG
Nov 8. 2018
9.50
Nov 9. 2018
10.49
1 Trading Days
10.44%
Link
LONG
Jan 15. 2019
7.99
Jan 17. 2019
8.81
2 Trading Days
10.30%
Link
LONG
Sep 9. 2019
3.07
Sep 25. 2019
3.77
12 Trading Days
23.03%
Link
LONG
Nov 21. 2019
4.15
Dec 6. 2019
4.44
10 Trading Days
6.88%
Link
LONG
Apr 14. 2020
2.83
May 1. 2020
3.36
13 Trading Days
18.68%
Link
LONG
Nov 19. 2020
3.32
Dec 9. 2020
4.10
13 Trading Days
23.46%
Link
LONG
Feb 4. 2021
4.52
Feb 17. 2021
5.88
8 Trading Days
30.18%
Link
LONG
May 18. 2021
3.96
Jun 17. 2021
4.53
21 Trading Days
14.33%
Link
LONG
Aug 23. 2021
4.91
Sep 8. 2021
5.25
11 Trading Days
6.99%
Link
LONG
Sep 13. 2021
9.15
Sep 14. 2021
11.06
1 Trading Days
20.87%
Link
Company Information
Stock Symbol
LIFE
Exchange
NasdaqGS
Company URL
http://www.atyrpharma.com
Company Phone
858-731-8389
CEO
John D. Mendlein
Headquarters
California
Business Address
3545 JOHN HOPKINS COURT, STE #250, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001339970
About

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.

Description

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading